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Abstract
Introduction: Neu (HER2/ErbB2) is overexpressed in 25% to 30% of human breast cancer, correlating with a poor
prognosis. Researchers in previous studies who used the mouse mammary tumor virus Neu-transgenic mouse
model (MMTV-Neu) demonstrated that the Neu-YB line had increased production of CXCL12 and increased
metastasis, whereas the Neu-YD line had decreased metastasis. In this study, we examined the role of increased
production of CXCL12 in tumor cell invasion and malignancy.
Methods: We studied invasion in the tumor microenvironment using multiphoton intravital imaging, in vivo
invasion and intravasation assays. CXCL12 signaling was altered by using the CXCR4 inhibitor AMD3100 or by
increasing CXCL12 expression. The role of macrophage signaling in vivo was determined using a colony-stimulating
factor 1 receptor (CSF-1R) blocking antibody.
Results: The Neu-YD strain was reduced in invasion, intravasation and metastasis compared to the Neu-YB and
Neu deletion mutant (activated receptor) strains. Remarkably, in the Neu-YB strain, in vivo invasion to epidermal
growth factor was dependent on both CXCL12-CXCR4 and CSF1-CSF-1R signaling. Neu-YB tumors had increased
macrophage and microvessel density. Overexpression of CXCL12 in rat mammary adenocarcinoma cells increased
in vivo invasion as well as microvessel and macrophage density.
Conclusions: Expression of CXCL12 by tumor cells results in increased macrophage and microvessel density and in
vivo invasiveness.
Introduction
Neu (HER2/ErbB2) is overexpressed in 25% to 30% of
human breast cancer, correlating with a poor prognosis
[1]. Neu is a member of the ErbB family of receptor tyr-
osine kinases, which are important mediators of signal
transduction for proliferation, survival, apoptosis, moti-
lity and invasion of cells. The ErbB receptors, consisting
of ErbB1 (epidermal growth factor receptor (EGFR)),
Her2/Neu (ErbB2), ErbB3 and ErbB4, can homodimerize
and heterodimerize, mediating ligand specificity and var-
ious signal transduction pathways [2]. At low expression
levels, Neu is unlikely to homodimerize [3]; however, it
is the preferred binding partner for the other ErbB
receptor tyrosine kinases and mediates the activation of
potent signal transduction pathways [4,5].
At high expression levels, Neu can homodimerize [6,7],
and the correlation of high levels of expression with poor
prognosis and clinical significance as a pharmacological
target has made the Neu receptor and its contributions
to metastasis and tumorigenesis important areas of study.
Because of its clinical significance, the Her2/Neu recep-
tor has been the focus of studies aimed at pharmacologi-
cally inhibiting its function. Trastuzumab (Herceptin;
Genentech, South San Francisco, CA, USA), a human
mAb, has been used to treat patients with Her2-positive
breast cancer [8]. However, the development of drug
resistance to trastuzumab treatment [9] underscores the
necessity to continue to investigate new ways to inhibit
the receptor pharmacologically. To study the Neu recep-
tor in vivo, a small deletion mimicking that found in
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patient tumors [10], was made in the extracellular
domain, and this construct (termed “Neu deletion
mutant (activated receptor),” or Neu-NDL) was
expressed by the mouse mammary tumor virus (MMTV)
promoter in transgenic mice [10,11]. A series of muta-
tions of Neu-NDL were made in which the major C-
terminal phosphorylated tyrosine residues were mutated
to phenylalanine, after which individual tyrosines were
added back and referred to as YA (1,028), YB (1,144), YC
(1,201), YD (1,227) and YE (1,253) [12].
Using these add-back mutants, we studied the contri-
butions of the tyrosine sites to tumorigenesis and lung
metastasis in transgenic mice. We found that the YA
site impaired transformation and/or tumorigenesis, the
YB site increased and the YD site decreased metastasis,
whereas the other add-back mutants exhibited metasta-
sis rates similar to that of Neu-NDL [12-14]. Metastasis
is a series of steps involving tumor growth, angiogenesis,
motility in the tumor microenvironment, invasion, intra-
vasation, extravasation and growth of metastases at a
distant site such as the lungs [15]. We chose to study
how the YB and YD sites diverge in their contributions
to early stages of metastasis by using the Neu-transgenic
mouse model and in vivo assays for tumor cell motility,
invasion and intravasation.
It has previously been shown on the basis of microar-
ray and ELISA that the YB line tumors express more
CXCL12 (stromal cell-derived factor 1) than the other
lines [14]. CXCL12 binds to the G protein-coupled
receptor CXCR4, which is often overexpressed in breast
cancer and has been correlated with poor clinical out-
come [16,17]. CXCL12-CXCR4 signaling has been
shown to play a role in tumor growth, invasion, angio-
genesis and bone marrow cell recruitment [18-23].
Recent studies of autocrine CXCL12 signaling have indi-
cated that it can induce the differentiation of monocytes
into a distinct population of proangiogenic, immunosup-
pressive macrophages in the tumor microenvironment
[24]. The results of these studies indicate that overex-
pression of CXCL12 in the tumor microenvironment
may alter invasive capacity, as well as the tumor-asso-
ciated immune cells that are recruited to tumors.
CXCL12 overexpression has been linked to increased
metastasis and poor prognosis [25]. Targeting the
CXCL12-CXCR4 signaling pathway has also been stu-
died in breast cancer treatment [26,27]. In this article,
we report that increased expression of CXCL12 by
breast cancer cells can lead to enhanced in vivo invasion
and increased macrophage and microvessel density.
Materials and methods
Animal models and cell lines
The experimental procedures involving all mice were
conducted in accordance with National Institutes of
Health regulations on the care and use of experimental
animals. This mouse study was approved by the Albert
Einstein College of Medicine animal use committee.
FVB mice transgenic for Neu and containing a small
activation deletion (Neu-NDL), as well as the add-back
mutants Neu-YB and Neu-YD [10,11], driven by the
MMTV long terminal repeat were studied. Mice were
followed for tumor growth and were used for experi-
ments when the largest tumor reached 2 cm in dia-
meter. Tumor volume was calculated as length ×
(width2 ÷ 2). For intravital imaging, the strains were
crossed with a strain expressing cyan fluorescent protein
(CFP) using the mammary gland-specific MMTV pro-
moter (MMTV-iCre-CAG-CAC-ECFP) as previously
described [28,29]. Xenograft tumors were made by
detaching rat mammary adenocarcinoma (MTLn3)
tumor cells with a solution containing PBS and 2 mM
ethylenediaminetetraacetic acid (EDTA) and then inject-
ing 1 × 106 cells, which were resuspended in PBS with
0.35% BSA (wt/vol), down from the heads to the right
fourth mammary fat pads of 5- to 7-week-old female
severe combined immunodeficient mice (National Can-
cer Institute, Frederick, MD, USA). For the in vivo inva-
sion assay, xenograft tumors were grown until they
reached 1.5 cm in diameter (about 4 weeks).
For culturing, primary tumors were chopped into
small pieces, washed in PBS and dissociated in PBS with
collagenase IV (final concentration of 6 mg/ml, C5138;
Sigma-Aldrich, St Louis, MO, USA), hyaluronidase (final
concentration of 1 mg/ml, H3506; Sigma-Aldrich) and
DNase I (final concentration of 0.25 mg/ml, D5025-
15KU; Sigma-Aldrich) for 30 minutes with continuous
agitation at 37°C. Following digestion, samples were
washed twice in sterile PBS and plated in DMEM/Ham’s
F-12 nutrient mixture (MT10092CV; Fisher Scientific,
Pittsburgh, PA, USA) supplemented with 10% fetal
bovine serum (FBS) (100-106; Gemini Bio-Products,
West Sacramento, CA, USA) and 0.5% penicillin-strep-
tomycin 100× solution (15140-122; Gibco/Life Technol-
ogies, Grand Island, NY, USA), 1 μg/ml hydrocortisone
(h4001; Sigma-Aldrich), 10 μg/ml insulin (I5523; Sigma-
Aldrich), 1 nM cholera toxin (C8052; Sigma-Aldrich),
nonessential amino acids and 10 nM epidermal growth
factor (EGF) (Life Technologies, Carlsbad, CA, USA).
To overexpress mouse CXCL12, a pCMVSport6-
CXCL12 plasmid (accession numbers BC006640 and
EMM1002-4021797; Open Biosystems/Thermo Scienti-
fic, Lafayette, CO, USA) was blunt-subcloned into the
NotI restriction enzyme site of the pQCXIP vector and
confirmed by plasmid sequencing. Retrovirus was gener-
ated by transfection of 293GP cells using Lipofectamine
2000 transfection reagent (11668-019; Invitrogen) with
12 μg of plasmid DNA and 4 μg of VSV-G plasmid
(vesicular stomatitus virus G protein). After 48 hours,
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supernatants were collected and used to transduce
MTLn3-GFP mammary adenocarcinoma cells [30] in
the presence of 4 μg/ml polybrene. All MTLn3 cell lines
were grown in a-minimum essential medium (a-MEM)
supplemented with 5% FBS and 0.5% penicillin-strepto-
mycin. Transduced cells were selected with 1 μg/ml pur-
omycin. To confirm expression of CXCL12, MTLn3
cells were seeded into six-well dishes in triplicate and
supernatants were collected 16 hours after the cultures
were confluent. Cells were counted at the time of collec-
tion to quantify the concentration in picograms per
milliliter for 1 × 106 cells. To evaluate CXCL12 secreted
in vitro by the Neu primary tumor cell lines, dissociated
tumor cells were seeded at equal density into six-well
dishes and supernatants were collected 16 hours after
the cells were confluent. Samples were spun down to
remove debris, frozen on dry ice and stored at -80°C.
CXCL12 was measured in the supernatant by ELISA
(DY460; R&D Systems, Minneapolis, MN, USA), with
triplicate measurements done for each sample. The con-
centration of CXCL12 was calculated in picograms per
milliliter using a standard curve from serial diluted
CXCL12 provided in the ELISA kit. MTLn3-GFP cells
transduced with JP1520 vector expressing CXCR4 were
kindly provided by Dr Lorena Hernandez [31].
Immunohistochemistry
Tumors were fixed in 10% buffered formalin for a mini-
mum of 24 hours, paraffin-embedded and sectioned for
H & E staining. Tumors were also fixed in periodate-
lysine-2% paraformaldehyde-0.05% glutaraldehyde
(PLPG) [32] at 4°C overnight, then stored in 70% etha-
nol at 4°C until embedded in paraffin. PLPG fixed
tumors were stained with F4/80 antibody at 1:50 dilu-
tion to identify macrophages as previously described
[33]. To quantify F4/80 staining, we chose ten random
fields of healthy tumor parenchyma and counted the
number of F4/80-stained macrophages using a 40× lens
objective for three tumors per strain. We found that for-
malin-fixed tumor vessels were poorly stained by anti-
CD34 antibodies; therefore, to stain tumor vasculature,
formalin-fixed, paraffin-embedded tumor sections were
stained with a rat anti-mouse endomucin (V.7C7) mAb
(sc-65495; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) at 1:50 dilution. To quantify endomucin staining,
ten random fields of healthy tumor parenchyma were
counted for endomucin-stained vessels using a 20× lens
objective for three tumors per strain. To detect tumor
lymphatic vessels, formalin-fixed, paraffin-embedded
tumor sections were stained with a rabbit anti-mouse
lymphatic vessel endothelial hyaluronan receptor pAb
(ab14917; Abcam, Cambridge, MA, USA) at 1:200 dilu-
tion. Anti-CXCR4 antibody was used at 1:300 dilution
(ab7199; Abcam).
To quantify lung metastasis in the Neu-transgenic
tumors, lung samples were fixed in 10% neutral formalin
buffer, embedded in paraffin, sectioned at 5 μm and
stained with H & E. H & E-stained sections spaced 250
μm apart were taken from the whole lung sample, and all
micrometastases were counted in every section using a
light microscope with a 10× lens objective. The efficiency
of lung metastasis was expressed in total number of
metastases in all lung sections for each animal with metas-
tases. To quantify lung metastases in the MTLn3 pQCXIP
and pQCXIP-CXCL12 tumors, lungs were removed after
4 weeks when the tumors had reached 1.5 cm in diameter
and fixed in 10% neutral formalin buffer, embedded in
paraffin, sectioned and stained with H & E to quantify the
total number of lung metastases in all lobes per section on
a light microscope with a 10× lens objective.
In vivo invasion assay
Tumors were allowed to reach 2-cm diameter (Neu-trans-
genic strains) or 1.5-cm diameter (MTLn3 xenografts) for
use in the in vivo invasion assay. The collection of the
invasive cell population from the primary tumors into
microneedles containing matrix and chemoattractant
using an in vivo invasion assay has been described pre-
viously [34]. The mice were anesthetized with isoflurane
(Aerrane; Baxter Healthcare Corp, Deerfield, IL, USA)
during the course of the assay. Briefly, tumors were first
penetrated with 33-gauge Hamilton needles (14-815-423;
Fisher Scientific), then these needles were replaced with
ones filled with L15 medium and 0.35% BSA containing
10% BD Matrigel™ Basement Membrane Matrix (356234;
BD, Franklin Lakes, NJ, USA) with or without chemoat-
tractant. Invasive cells were collected for 4 hours, then the
contents of the needles were extruded onto a coverslip by
using 0.5 μg/ml 4’,6-diamidino-2-phenylindole in PBS to
quantify the number of invasive cells with an Olympus
IX70 inverted microscope with a 10× lens objective and a
0.30 numerical aperture (NA) (Olympus America, Mel-
ville, NY, USA). The chemoattractant EGF (53003018;
Gibco/Life Technologies) was used at a concentration of
25 nM. To inhibit the CXCR4 receptor, the inhibitor
AMD3100 (A5602; Sigma-Aldrich) was used at a concen-
tration of 0.5 μM. To block and/or neutralize the colony-
stimulating factor 1 receptor (CSF-1R), a purified anti-
mouse CSF-1R mAb, AFS98 [35], kindly provided by Dr
Richard Stanley was used at a concentration of 15 μg/ml.
As a control antibody, a mouse immunoglobulin G (IgG)
antibody was used at the same concentration used for the
experimental CSF-1R antibody (012-000-007; Jackson
ImmunoResearch, West Grove, PA, USA).
Wound healing assay
Primary tumor cells were cultured for 1 week, passaged
into a new 10-cm culture dish and allowed to grow to
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confluence. We removed EGF from the media 24 hours
prior to performing wound healing assays. Cultures for
each of the strains were starved in DMEM/Ham’s F-12
nutrient mixture and 0.7% BSA (wt/vol) for 4 hours,
then a grid was drawn on the plate for reference and
four scratches were introduced using a pipette tip.
Images were taken at time 0, and cultures were treated
with buffer and 5 nM EGF. The Neu-YB strain was also
treated with 5 nM EGF + 100 nM AMD3100, 5 nM
EGF + 1 nM CXCL12 and 1 nM CXCL12. The wound
was allowed to heal for 12 hours, and images of the
same field were taken. Analysis was done using
TScratch software as previously described [36], and the
percentage of the wound area closed was calculated.
Chemotaxis assays
Murine bone marrow-derived macrophages (BMMs)
were isolated as described previously [37] and were
grown in a-MEM containing 15% FBS, 360 ng/ml recom-
binant human CSF-1 (Chiron Corp, Emeryville, CA,
USA) and antibiotics. Cell migration was measured using
a transmigration chamber assay with 8-μm pore size
inserts (BD Falcon, Franklin Lakes, NJ, USA) according
to the manufacturer’s instructions. Briefly, the inserts
were placed into 24-well plates containing a-MEM in the
presence or absence of 50 ng/ml CXCL12. Cells (n = 1 ×
106) were then loaded onto the inserts and incubated at
37°C for 4 hours. Cells that had migrated through the
inserts were counted using phase microscopy, and the
average number of cells in five different fields was calcu-
lated. For MTLn3-GFP-CXCR4 cells, a 48-well microche-
motaxis chamber (Neuro Probe, Inc, Cabin John, MD,
USA) was used as described previously [38]. Briefly, cells
were starved for 3 hours in L15 medium supplemented
with 0.35% BSA (L15B) at 37°C. Two hours before micro-
chemotaxis chamber assembly, an 8-μm pore filter
(Neuro Probe, Inc) was coated with 3.53 mg/ml rat tail
collagen type I (354249; BD) in Ca2+- and Mg2+-free Dul-
becco’s PBS. After starvation, cells were detached using
PBS-EDTA and 30,000 cells per well were loaded into
the top wells of the chamber in L15B medium. Cells were
allowed to migrate for 4 hours at 37°C, with the bottom
wells filled with CXCL12 diluted in L15B or with L15B
alone. The filter was then taken out and fixed in 10% par-
aformaldehyde for 1 hour, nonmigrating cells were
removed from the top surface of the filter and the
remaining cells on the lower surface were stained over-
night with hematoxylin (CS402-1D; Fisher Scientific).
The membrane was washed in deionized water, and
migrated cells were counted using a light microscope.
Immunofluorescence microscopy
Live, nonpermeabilized murine BMMs were stained with
1:250 anti-CXCR4 antibody (ab7199; Abcam) and Alexa
Fluor 568 dye donkey anti-rabbit IgG. Images were
taken using the Plan Apochromat (Plan Apo) 60× oil
immersion lens/1.40-NA phase 3 objective of an Olym-
pus IX71 microscope equipped with a charge-coupled
device camera (Olympus America).
Quantitative RT-PCR
mRNA was isolated from cells in culture, and 100 ng of
cDNA were used for quantitative RT-PCR. Specific pri-
mers for mouse CXCR4 (forward: 5’-TGGTGTTTCA
ATTCCAGCAT-3’ and reverse 5’-CGATGCTCTCG
AAGTCACAT-3’) were obtained from RealTimePri-
mers.com (mouse chemokine (C-X-C motif) receptor 4,
VMPS-1496; Real Time Primers LLC, Elkins Park, PA,
USA) and used with SYBR Green PCR Master Mix
(SuperArray PA-012; SABiosciences, Frederick, MD,
USA).
Blood burden assay
Mice were anesthetized with isoflurane, and blood was
taken from the right atrium by cardiac puncture using a
25-gauge needle and a 1-ml syringe coated with and
containing 0.1 ml of heparin. Blood (0.5 to 1 ml) was
drawn and plated into 10-cm-diameter dishes filled with
DMEM/Ham’s F-12 nutrient mixture and 20% FBS. The
next day the plates were replaced with fresh medium.
After 7 days, the number of individual cells in the dish
were counted. Tumor blood burden (tumor cells per
milliliter of blood) was calculated as the total number of
tumor cells in the dish divided by the volume of blood
taken.
Intravital imaging
Animals with an average tumor diameter of 2 cm were
placed under isoflurane anesthesia, and skin flap sur-
gery was performed to expose the tumor. These ani-
mals were placed on an inverted microscope while
under continuous anesthesia, and tumor cells were
imaged using a Bio-Rad Radiance 2000 MP multipho-
ton microscope (Bio-Rad Laboratories, Hercules, CA,
USA) or on an Olympus FluoView FV1000-MPE mul-
tiphoton laser scanning microscope (Olympus Amer-
ica). The CFP fluorescence was measured at a
wavelength of 880 nm using a Plan Apo 20× water
immersion lens/0.75-NA objective with a 3× zoom or a
Plan Apo 25× water immersion lens/1.05-NA objective
with a 2.3× zoom. Time-lapse imaging was done over
30 minutes with 2-minute intervals to collect a 100-
μm stack. Motility was assessed using ImageJ software
(National Institutes of Health, Bethesda, MD, USA),
and the average total cell motility was quantified per
50-μm Z-stack (five sections imaged at 10-μm inter-
vals). A motile cell was defined as any protrusion at
least one-half cell diameter in length.
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Results
Neu-YD strain exhibited decreased spontaneous invasion,
intravasation and metastasis compared to Neu-NDL and
Neu-YB strains
Metastatic properties were compared between animals
with similar tumor volumes. At the time of analysis, the
total tumor volume averaged 3 to 3.5 ml and the largest
tumor averaged 2 to 2.5 ml (Figures 1A and 1B). Inter-
estingly, the Neu-YD strain grew tumors the fastest, tak-
ing an average of 24 weeks compared to about 30 weeks
for the Neu-NDL and Neu-YB strains (Figure 1C).
Despite growing tumors faster (P < 0.005), the Neu-YD
strain had decreased invasion, intravasation and metas-
tasis (Figure 2). We evaluated invasion using the in vivo
invasion assay previously described [34] by inserting
microneedles containing EGF and Matrigel™ into the
tumor to collect the invasive cell population. The Neu-
YD tumor cells were significantly less invasive to EGF
compared to those of the Neu-YB and the Neu-NDL
strains (Figure 2A). To determine whether the decreased
invasion of the Neu-YD strain correlated with a
decreased number of tumor cells in the blood, we evalu-
ated intravasation. The number of intravasated cells for
the Neu-YD strain was approximately 200 cells/ml of
blood. This number was significantly decreased com-
pared to the Neu-YB strain, which averaged 850 cells/ml
of blood, and the Neu-NDL strain, which averaged 940
cells/ml of blood (Figure 2B). The number of sponta-
neous metastases were counted in H & E sections
throughout all lobes of the lungs in mice containing
metastases. The Neu-YD strain had significantly fewer
metastases than the Neu-YB or Neu-NDL strains (Figure
2C). This indicates the YB site, but not YD, is sufficient
for lung metastasis. These results suggest that the defect
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Figure 1 Evaluation of tumor growth, burden and age. (A) Size of largest tumor at time of analysis. There was no significant difference
between the Neu deletion mutant (activated receptor) (Neu-NDL), Neu-YD and Neu-YB strains. (B) Total tumor volume at time of analysis.
Transgenic mice developed multiple tumors. All tumors were measured, and the volumes were added. There was no significant difference in
cumulative tumor volume, which averaged about 4 ml. (C) Average age in weeks at time of analysis. Data are means and SEM. **P < 0.005 by t-
test, n = 18 to 22 mice per strain.
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in Neu-YD metastasis is due to defects in invasion and
intravasation. To determine whether defects in invasion
and intravasation were correlated with motility in the
tumor microenvironment, we used intravital multipho-
ton microscopy to evaluate tumor cell motility in vivo
(Figure 3 and Additional files 1, 2 and 3). We found
that the Neu-YD tumors had slightly fewer motile cells
than Neu-NDL. Neu-YB tumors had significantly more
motile cells than either the Neu-NDL or Neu-YD
tumors.
Neu-YB strain has more macrophages than Neu-YD and
Neu-NDL strains in tumor parenchyma
In addition to our findings that the Neu-YB strain had
increased invasion, intravasation, metastasis and motility
compared to the Neu-YD strain, it has also been shown
to be unique in its tumor morphology and expression
profile compared to the other Neu lines [14,39]. Our
past studies have been focused on the role of macro-
phages in a tumor cell and macrophage paracrine loop
driving in vivo invasion [40,41]. We were interested to
see whether differences in the number of macrophages
in the tumor correlated with the differences we found in
Neu-YB and Neu-YD in vivo invasion and tumor cell
motility. We found that the Neu-YB tumors had, on
average, twice the number of F4/80-positive macro-
phages per square millimeter compared to the Neu-YD
tumors (P < 0.0005) and also had significantly more
than the Neu-NDL control (P < 0.05) (Figures 4A and
4B). The Neu-YD strain also had fewer macrophages
than the Neu-NDL (P < 0.005). In addition to macro-
phage recruitment, we looked at the distribution of vas-
culature and lymphatics in the various strains. We
observed no difference in lymphatics (Additional file 4),
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Figure 2 Neu-YD strain exhibits decreased invasion, intravasation and metastasis compared to Neu-NDL and Neu-YB strains. (A) The in
vivo invasion assay was performed, allowing tumor cells to invade over 4 hours into microneedles containing 25 nM epidermal growth factor
(EGF) or buffer. Neu-NDL = Neu deletion mutant (activated receptor). Data are means and SEM. **P < 0.005 by t-test, n = three to five mice per
strain and five to seven needles per condition. (B) A blood burden assay was performed to evaluate intravasation. The number of single cells per
milliliter of blood were counted. Data are means and SEM. *P < 0.05 by t-test, n = 8 to 11 mice per strain. (C) H & E-stained sections (5 μm
each) spaced 250 μm apart were taken from the whole lung sample, and metastases were counted in every section. The efficiency of lung
metastasis is represented as the total number of metastases in all lung sections for each animal that had metastases. Data are means and SEM.
*P < 0.05 and ** p < 0.005 by Mann-Whitney U test; n = 16 Neu-NDL mice, 15 Neu-YD mice and 8 Neu-YB mice.
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but saw significantly more vasculature staining in the
Neu-YB strain compared to the Neu-NDL strain (P <
0.05) and the Neu-YD strain (P < 0.0005) (Additional
file 5). The Neu-YD strain also had significantly fewer
vessels than the Neu-NDL strain (P < 0.005). The
increase in vasculature seen in the Neu-YB strain is con-
sistent with studies in which CXCL12 has been corre-
lated with increased angiogenesis and hematopoiesis
[23].
EGF-induced in vivo invasion of Neu-YB tumor cells is
dependent on CXCR4-CXC12 signaling in the tumor
microenvironment
Because Neu-YB tumor cells have been shown to
express more CXCL12 than the other mutants and Neu-
NDL [14], we investigated whether CXCR4 signaling
plays a role in EGF-induced in vivo invasion in that
tumor. EGF-induced in vivo invasion of the Neu-YB
strain was significantly inhibited by the CXCR4 inhibitor
AMD3100 (P < 0.0005) (Figure 5A). The Neu-YD and
Neu-NDL tumor cells were not significantly affected by
AMD3100 inhibition of CXCR4. This suggests that the
CXCL12 expressed by the Neu-YB tumor cells was
necessary for EGF induced in vivo invasion. We have
previously shown that EGF-induced in vivo invasion in
the Neu-NDL model is dependent on a CSF-1-EGF
paracrine loop [41]. To test this in the Neu-YB line, we
used a CSF-1R-blocking antibody. The antibody inhib-
ited EGF-induced in vivo invasion in the YB strain, as
well as in the YD and Neu-NDL tumors, confirming
that the paracrine loop was still operating (Figure 5B).
To evaluate in vitro migration, monolayers were
grown from primary cells derived from the Neu-NDL,
Neu-YD and Neu-YB primary tumors in vitro, and
wound healing assays were carried out in the presence
of EGF, EGF and AMD3100, and CXCL12. There was
decreased EGF-induced in vitro migration in the Neu-
YB and Neu-YD strains compared to the Neu-NDL in
the wound healing assay (P < 0.0005) (Figure 5C). We
evaluated CXCL12 secretion by ELISA in the primary
cultures and found that the Neu-YB strain expressed
more CXCL12 than the Neu-NDL and Neu-YD strains
(Additional file 6, Supplemental Figure 3A). We con-
firmed that there were similar levels of CXCR4 receptor
in all three tumor types (Additional file 6, Supplemental
Figures 3B and 3C). However, there was no effect of
CXCR4 inhibition or stimulation on in vitro wound
healing in the Neu-YB strain (Figure 5D). The tumor
cells did not respond to CXCL12 in a chemotaxis assay
either (Additional file 6, Supplemental Figure 3D).
IVI tumor cell motility
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Figure 3 Motility in the tumor microenvironment. Intravital imaging (IVI) using multiphoton microscopy of primary mammary tumors from
transgenic Neu deletion mutant (activated receptor) (Neu-NDL), Neu-YD and Neu-YB cyan fluorescent protein mice. Thirty-minute time-lapse Z-
series were collected, and the average total cell motility was quantified per 50-μm Z-stack (five sections imaged at 10-μm intervals). Data are
means and SEM of 27 to 32 separate Z-stacks. *P < 0.05, **P < 0.005 by Mann-Whitney U test; n = 13 Neu-NDL mice, n = 8 Neu-YD mice and n
= 12 Neu-YB mice.
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Chemotaxis and wound healing assays with CXCL12
were also performed with MTLn3-CXCR4-overexpres-
sing cells as positive controls (Additional file 6, Supple-
mental Figures 3D and 3E). The results of these studies
indicate that the tumor cells are not activated through
autocrine stimulation by CXCL12, but rather that a
paracrine loop involving CXCR4-CXCL12 signaling in
the tumor microenvironment is needed for EGF-induced
in vivo invasion in Neu-YB tumors.
Overexpression of CXCL12 in MTLn3 rat adenocarcinoma
cells increases in vivo invasion and increases macrophage
density in tumors
To confirm that CXCL12 secretion by tumor cells can
result in an increase in macrophage density and tumor
cell in vivo invasion, we overexpressed CXCL12 in
MTLn3 cells (Additional file 7). CXCL12 overexpression
significantly increased in vivo invasion to EGF compared
to the empty vector control (Figure 6A). Similarly to the
Neu-YB tumors, CXCL12 overexpression in MTLn3
cells increased the number of macrophages present in
the tumor parenchyma approximately twofold (P <
0.005) (Figures 6B and 6C). In addition, we evaluated
CXCR4 expression levels on macrophages and tumor
cells in the MTLn3 tumors and found that the macro-
phages in these tumors expressed more CXCR4 than
the tumor cells did (Additional file 8, Supplemental Fig-
ure 5A). Of note, there was no significant difference in
the amount of CXCR4 receptor on macrophages from
the CXCL12-overexpressing tumors compared to the
control (Additional file 8, Supplemental Figure 5A).
Moreover, we found that CXCL12 induced the migra-
tion of CXCR4-positive macrophages (Additional file 8,
Supplemental Figures 5B and 5C). CXCL12 overexpres-
sion had no effect on tumor size. However, we did
observe a trend toward increased numbers of metastases
with CXCL12 expression (Additional file 9, Supplemen-
tal Figures 6A and 6B). Consistent with our observation
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Figure 4 F4/80 staining indicates the Neu-YB strain recruits more macrophages into the tumor parenchyma. (A) F4/80 staining was
quantified by using a 40× lens objective and counting the number of F4/80-stained macrophages per field (n = 3 tumors per strain and 10
random fields per tumor). Data shown are means and SEM. *P < 0.05, **P < 0.005, ***P < 0.0005 by t-test. (B) Representative fields of F4/80
staining taken at low magnification (scale bar = 200 μm) (i) and high magnification (scale bar = 25 μm) (ii). Neu-NDL = Neu deletion mutant
(activated receptor).
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that the Neu-YB tumors, which express increased
amounts of CXCL12, have a higher microvessel density,
we confirmed that CXCL12 expression in MTLn3 cells
also significantly increases the number of blood vessels
in the primary tumors compared to control MTLn3
tumors (Additional file 9, Supplemental Figures 6C
through 6E).
Discussion
In this paper, we describe how the expression of CXCL12
by breast tumor cells can enhance in vivo invasion in the
tumor microenvironment through recruitment of
macrophages. We initially analyzed the Neu-transgenic
tumors. The Neu-YB and Neu-YD strains had different
metastatic capacities, which is consistent with previously
published data [14]. We found that the Neu-YD tumor
cells are defective in wound healing in vitro and that this
correlates with decreased in vivo invasion in the primary
tumor and decreased metastasis to the lungs. The Neu-YB
tumor cells showed a reduction in wound healing in vitro
similar to that of the Neu-YD cells. In vivo, however, they
exhibited increased motility compared to both the Neu-
NDL and Neu-YD strains and increased in vivo invasion,
intravasation and metastasis compared to the Neu-YD
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Figure 5 Epidermal growth factor-induced in vivo invasion is dependent on CXCR4/CXCL12 paracrine signaling in the tumor
microenvironment. (A) In vivo invasion assay performed by infusing 25 nM epidermal growth factor (EGF) and EGF + 0.5 μM CXCR4 inhibitor
AMD3100 through microneedles inserted into the primary tumor to collect the invasive cell population over 4 hours. Neu-NDL = Neu deletion
mutant (activated receptor). Data are means and SEM. ***P < 0.0005 by t-test, n = three to five mice per strain and five to seven needles per
condition. (B) In vivo invasion assay performed with 25 nM EGF + control rat immunoglobulin G (IgG) antibody or EGF + colony-stimulating
factor 1 receptor (CSF-1R) blocking antibody (aCSF-1R IgG) in the needles. Data are means and SEM. ***P < 0.0005 by t-test, n = three to five
mice per strain and five to seven needles per condition. (C) In vitro wound healing assays in the absence (Buffer) or presence of 5 nM EGF (EGF).
Data are means and SEM. *P < 0.05, **P < 0.005 and ***P < 0.0005 by t-test, n = 3 tumors per strain and at least 10 fields per condition. (D) In
vitro wound healing assays were performed with confluent primary tumor tissue in the presence of buffer (Buffer), 5 nM EGF alone (EGF), 5 nM
EGF with 100 nM AMD3100 (EGF + AMD3100), 5 nM EGF with 1 nM CXCL12 (EGF + CXCL12) or 1 nM CXCL12 alone (CXCL12). Data are means
and SEM. **P < 0.005 by t-test, n = 3 tumors and at least 10 fields per condition.
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strain. The increased in vivo invasion was dependent on
CXCR4 function, which is consistent with the overexpres-
sion of CXCL12 by Neu-YB tumors. We then directly
tested the role of CXCL12 expression in tumor cells by
overexpressing this ligand in MTLn3 cells. Increased
CXCL12 expression in MTLn3 cells resulted in increased
in vivo invasion, macrophage density and microvessel
numbers, which is consistent with our observations of
Neu-YB tumors.
The CXCR4-CXCL12 signaling axis contributes to
metastasis and clinical outcomes in breast cancer.
CXCR4 expression in breast cancer cells has been
shown to increase metastasis by homing of tumor cells
to sites of increased CXCL12 expression, such as the
lymph nodes [16]. Overexpression of CXCL12 increased
in vitro invasion and migration of human breast cancer
MDA-MB-231 cells [25], and overexpression of CXCL12
was seen in breast cancer patients with lymph node-
positive metastatic disease with a poor prognosis [25].
We have directly evaluated the role of increased
CXCL12 expression in in vivo tumor cell invasion,
where the tumor microenvironment and paracrine loops
with supporting stromal cells can influence tumor cell
behavior. We found that inhibiting CXCR4 with
AMD3100 reduced Neu-YB in vivo invasion to EGF to
levels similar to those seen in Neu-YD. This indicates
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macrophages. (A) The in vivo invasion assay was performed with MTLn3 empty vector and CXCL12-overexpressing cell line tumors, allowing
tumor cells to invade over 4 hours into microneedles containing 25 nM EGF or buffer. Data shown are means and SEM. *P < 0.05 and ***P <
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that invasion to EGF is dependent on CXCL12-CXCR4
signaling in the tumor microenvironment, specifically in
the Neu-YB strain.
We also saw increased numbers of macrophages in the
Neu-YB tumor parenchyma. Because there is an EGF-
CSF-1R paracrine loop with macrophages inducing
tumor cell invasion, we tested whether CXCL12 would
act on the Neu-YB tumor cells to increase invasion in
an autocrine manner or in a paracrine loop with macro-
phages. As we have shown previously for the EGF-CSF1
paracrine loop [40], a blocking antibody to the CSF-1R
decreased in vivo invasion in the YB strain, indicating
that in vivo invasion of the YB tumor cells was still
dependent upon the EGFR-CSF-1R paracrine loop inter-
action with macrophages. We found that, in vitro, both
Neu-YB and Neu-YD primary tumor cells had impaired
wound healing to EGF compared to the Neu-NDL cells.
Addition of CXCL12 did not increase in vitro wound
healing in the Neu-YB cultures, and AMD3100 did not
inhibit it, supporting the hypothesis that in this model
CXCL12 contributes to a paracrine loop between tumor
cells and macrophages within the tumor microenviron-
ment. We hypothesize that the increased macrophage
recruitment in the Neu-YB tumors results in enhanced
paracrine loop invasion, which compensates for the
reduced inherent invasiveness in the Neu-YB cells. Thus
the inherent defect in Neu-YB tumor cell invasiveness is
compensated by increased CXCL12 expression. To con-
firm that CXCL12 expression can produce such effects,
we overexpressed CXCL12 in MTLn3 breast cancer
cells and observed increased in vivo invasion as well as
increased tumor-associated macrophage recruitment.
There are a number of possible mechanisms by which
increased CXCL12 expression could enhance tumor
invasiveness and malignancy. The results of the present
study indicate that CXCL12 overexpression itself, in dif-
ferent tumor models, can recruit more macrophages.
The increased recruitment of tumor-associated macro-
phages may induce increased tumor cell motility and
invasion simply by increasing the number of macro-
phages that contribute to paracrine loop signaling
[40,42-45]. In addition, secreted CXCL12 signaling to
CXCR4 receptors on macrophages can increase EGFR
ligand shedding [46], and this could also contribute to
increased tumor cell motility and invasion. Alternatively,
in tumors expressing CXCR4, autocrine signaling has
been shown to increase migration and invasion in other
models [25,47]. CXCL12 can transactivate the EGFR
and Neu through Src activation [43,48], and EGF can
potentiate CXCL12-driven chemotaxis [49]. Our in vitro
studies showing that Neu-YB cells are similar to Neu-
YD cells in the wound healing in vitro assay, with the
addition of CXCL12 or inhibition of CXCR4 having no
effect, argue against autocrine signaling’s contributing to
the invasion of Neu-YB tumor cells.
In this study, we also found increased microvessel
density in tumors that overexpressed CXCL12. Because
the tumor cells we studied did not show strong respon-
siveness to CXCL12, the increased microvessel density
in tumors that overexpressed CXCL12 most likely
reflects a stromal response to CXCL12. In particular,
the increased macrophage density may also give rise to
increased angiogenesis through secretion of angiogenic
factors such as vascular endothelial growth factor
[50-53]. Intriguingly, we did not find that increased
microvessel density was correlated with enhanced tumor
growth. However, the increased microvessel density
could result in increased intravasation through the pre-
sence of a higher density of entrance sites into the
blood, with a corresponding increase in the formation of
metastases.
Conclusion
In summary, we have found that secretion of CXCL12
by breast cancer cells can enhance invasion in vivo and
recruitment of macrophages to the primary tumor. This
enhancement of invasion depends upon CXCR4 signal-
ing and most likely occurs through activation of CXCR4
on macrophages, resulting in increased paracrine inter-
actions with tumor cells in the tumor microenviron-
ment. Increased CXCL12 secretion also gives rise to
increased microvessel density, which may also be
mediated by tumor-associated macrophages, and contri-
butes to altered tumor architecture. These results
demonstrate how tumor cell regulation of the local cel-
lular microenvironment can increase invasion and moti-
lity and thus contribute to enhanced tumor malignancy.
Additional material
Additional file 1: Supplemental movies 1, 2 and 3. The Neu-YB
(Additional file 3) mouse strain tumors had more motility than the Neu
deletion mutant (activated receptor) (Neu-NDL) (Additional file 1) or Neu-
YD (Additional file 2) mouse strains in the tumor microenvironment.
Tumors were exposed by performing skin flap surgery, and the murine
tumor tissue was imaged with an Olympus FluoView FV1000-MPE
multiphoton laser scanning microscope. Cyan fluorescent protein-
expressing tumors were excited at a wavelength of 880 nm using a 25×
1.05-numerical aperture water immersion lens objective with a 2.3×
zoom. Time-lapse imaging was done over 30 minutes, collecting a 3D
image stack through 100 μm every 2 minutes in 5 μm steps in the z axis.
Arrows indicate areas of cell motility. Scale bar = 25 μm.
Additional file 2: Supplemental movies 1, 2 and 3. The Neu-YB
(Additional file 3) mouse strain tumors had more motility than the Neu
deletion mutant (activated receptor) (Neu-NDL) (Additional file 1) or Neu-
YD (Additional file 2) mouse strains in the tumor microenvironment.
Tumors were exposed by performing skin flap surgery, and the murine
tumor tissue was imaged with an Olympus FluoView FV1000-MPE
multiphoton laser scanning microscope. Cyan fluorescent protein-
expressing tumors were excited at a wavelength of 880 nm using a 25×
1.05-numerical aperture water immersion lens objective with a 2.3×
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zoom. Time-lapse imaging was done over 30 minutes, collecting a 3D
image stack through 100 μm every 2 minutes in 5 μm steps in the z axis.
Arrows indicate areas of cell motility. Scale bar = 25 μm.
Additional files 3: Supplemental movies 1, 2 and 3. The Neu-YB
(Additional file 3) mouse strain tumors had more motility than the Neu
deletion mutant (activated receptor) (Neu-NDL) (Additional file 1) or Neu-
YD (Additional file 2) mouse strains in the tumor microenvironment.
Tumors were exposed by performing skin flap surgery, and the murine
tumor tissue was imaged with an Olympus FluoView FV1000-MPE
multiphoton laser scanning microscope. Cyan fluorescent protein-
expressing tumors were excited at a wavelength of 880 nm using a 25 ×
1.05-numerical aperture water immersion lens objective with a 2.3×
zoom. Time-lapse imaging was done over 30 minutes, collecting a 3D
image stack through 100 μm every 2 minutes in 5 μm steps in the z axis.
Arrows indicate areas of cell motility. Scale bar = 25 μm.
Additional file 4: Supplemental Figure 1 Immunohistochemistry
indicates no difference in density of lymphatic vessels in the Neu
primary tumors. Tumors from the Neu deletion mutant (activated
receptor) (Neu-NDL), Neu-YD and Neu-YB mice were fixed in 10%
buffered formalin, then sectioned and stained using the lymphatic vessel
endothelial hyaluronan receptor (LYVE-1) antibody against mouse LYVE-1
to stain lymphatic endothelial cells. Representative images of each stain
are shown. Scale bar = 100 μm.
Additional file 5: Supplemental Figure 2 Neu-YB tumors show
increased vasculature. Tumors from the Neu deletion mutant (activated
receptor) (Neu-NDL), Neu-YD and Neu-YB strains were fixed in 10%
buffered formalin, then sectioned and stained using an endomucin
antibody to detect vasculature. (A) Vessels were quantified using a 20×
lens objective. Ten random fields per tumor were counted (n = three
tumors per strain). Data are means and SEM. *P < 0.05, **P < 0.005 and
***P < 0.0005. (B) Representative images of each strain are shown. Scale
bar = 100 μm.
Additional file 6: Supplemental Figure 3 Further characterization of
CXCL12 and CXCR4 in the Neu tumors. (A) Primary culture cell lines
were counted and seeded in duplicate and supernatants were collected
for CXCL12 quantification 16 hours after cultures were confluent. ELISA
was done in triplicate for each sample using the CXCL12 mouse ELISA
from R&D Systems. Data are means and SEM. (B) Tumors from the Neu
deletion mutant (activated receptor) (Neu-NDL), Neu-YD and Neu-YB
strains were fixed in 10% buffered formalin, then sectioned and stained
using anti-CXCR4 antibody. Representative images for each strain are
shown. Scale bar = 50 μm. (C) mRNA was extracted from the Neu
primary tumor cells in culture. Levels of CXCR4 are represented as
average change in threshold cycle values normalized to Neu-NDL (n =
three samples per strain). Data are means and SEM. (D) CXCL12-induced
chemotaxis of primary tumor cells (top) or mammary adenocarcinoma
(MTLn3) CXCR4-overexpressing cells (bottom) was determined using a
microchemotaxis Boyden chamber assay. Data are means and SEM. (E) In
vitro wound healing assay with MTLn3 CXCR4 cells in the absence
(Buffer) or presence of 1 nM CXCL12. Data are means and SEM, N = 3, 10
fields per condition. *P < 0.05.
Additional file 7: Supplemental Figure 4 Mammary adenocarcinoma
GFP CXCL12 cell line overexpressed CXCL12 compared to empty
vector control cells. Mammary adenocarcinoma (MTLn3) GFP CXCL12
and MTLn3 GFP pQCXIP control cell lines were plated in triplicate, and
supernatants were collected from confluent cultures after 16 hours. Cells
were counted to normalize for cell number, and ELISA was performed in
triplicate for each sample using the CXCL12 mouse ELISA from R&D
Systems. Data are means and SEM. ***P < 0.0005.
Additional file 8: Supplemental Figure 5 Macrophage CXCR4
expression and responses to CXCL12. (A) Expression of CXCR4 on
tumor cells and macrophages in vivo. Mammary adenocarcinoma tumors
formed from MTLn3 GFP cells stably transduced with pQCXIP-CXCL12 or
pQCXIP empty vector control were dissociated and labeled with CD45-
AF700, F4/80-PerCP and CXCR4-PE antibodies, respectively. Cells were
washed and stained with 4’,6-diamidino-2-phenylindole as a viability
marker. Samples were analyzed using flow cytometry, and data were
processed using FlowJo software. Tumor cells were CD45-, F4/80- and
GFP+. Macrophages were CD45+ and F4/80+. The mean fluorescence of
CXCR4-phycoerythrin is shown in representative images (n = three
tumors for each cell line). (B) Expression of CXCR4 on macrophages in
vitro. Representative images of live murine bone marrow-derived
macrophages (BMMs) stained for control or CXCR4 (right panels).
Matched phase-contrast images are shown (left panels). Scale bar = 10
μm. (C) Chemotaxis of macrophages in vitro. CXCL12-induced
chemotaxis of BMMs with 50 ng/ml CXCL12 was determined using a
transwell assay and is expressed as cells per field (n = 3). Data are means
and SEM. ***P < 0.0003.
Additional file 9: Supplemental Figure 6 Tumor volume, lung
metastasis and vasculature of mammary adenocarcinoma GFP
CXCL12 tumors. (A) Tumor volume was calculated by measuring the
length and width of each tumor. There were no significant differences in
tumor volume between the CXCL12 overexpressors and empty vector
controls. (B) Lung metastasis was quantified as the total number of
micrometastases in all lobes per section stained by H & E. The mammary
adenocarcinoma (MTLn3) CXCL12 tumors displayed a trend toward
increased metastases. Error bars = SEM (n = ten mice). (C) MTLn3 empty
vector control and MTLn3 CXCL12 tumors were fixed in 10% buffered
formalin, then sectioned and stained using endomucin antibody against
the mouse endothelial cells to stain vasculature. Vessels were quantified
using a 20× lens objective. Ten random fields per tumor were counted
(n = three tumors per strain). Data are means and SEM. ***P < 0.0002.
(D) and (E) Representative images of the control tumors (D) and CXCL12
tumors (E) are shown. Scale bar = 100 μm.
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